| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.0014 | 1 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |